BCL2 and B-cell chronic lymphocytic leukemia: In the new era of novel therapies, the choice of CLL treatment varies from conventional chemotherapy to highly effective regimens such as anti-CD20 monoclonal antibodies, BTK inhibitors, Bcl-2 inhibitors, and PI3K inhibitors (4–6).